Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study
Focus · 2026-04 · 24 (2) · 212-222
DOI: 10.1176/appi.focus.26024111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Focus, 2026-04. Verfasst von Naim Zaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Depression
Abstract (Originalsprache)
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3 "parent" studies could continue esketamine treatment, combined with an oral antidepressant, by enrolling in phase 3, open-label, long-term extension study, SUSTAIN-3. Based on their status at parent-study end, eligible participants entered a 4-week induction phase followed by an optimization/maintenance phase, or directly entered the optimization/maintenance phase of SUSTAIN-3. Intranasal esketamine dosing was flexible, twice-weekly during induction and individualized to depression severity during optimization/maintenance. At the interim data cutoff (01 December 2020), 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance. Mean (median) cumulative duration of maintenance esketamine treatment was 31.5 (37.7) months (totaling 2769 cumulative patient-years). Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis. Mean Montgomery-Åsberg Depression Rating Scale (MADRS) total score decreased during induction, and this reduction persisted during optimization/maintenance (mean [SD] change from the baseline to the endpoint of each phase: induction -12.8 [9.73]; optimization/maintenance +1.1 [9.93]), with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively. Improvement in depression ratings generally persisted among participants who remained in maintenance treatment, and no new safety signal was identified during long-term treatment (up to 4.5 years) using intermittent-dosed esketamine in conjunction with daily antidepressant. Appeared originally in Neuropsychopharmacology 2023; 48: 1225-1233.
Autor:innen und Institutionen
- Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.
- Department of Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA.
- Department of Neuroscience, Janssen Research & Development, LLC, San Diego, CA, USA.
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
- Department of Neuroscience, Janssen Research & Development Belgium, Beerse, Belgium.
ORCID-Profile: Gerard Sanacora
Zitieren
APA
Zaki, N., Chen, L. N., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D. J. (2026). Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study. Focus, 24(2), 212-222. https://doi.org/10.1176/appi.focus.26024111
Vancouver
Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, et al. Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study. Focus. 2026;24(2):212-222. doi:10.1176/appi.focus.26024111
BibTeX
@article{Zaki2026,
author = {Zaki, Naim and Chen, Li Nancy and Lane, Rosanne and Doherty, Teodora and Drevets, Wayne C and Morrison, Randall L and Sanacora, Gerard and Wilkinson, Samuel T and Popova, Vanina and Fu, Dong-Jing},
title = {Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study},
journal = {Focus},
year = {2026},
volume = {24},
number = {2},
pages = {212--222},
doi = {10.1176/appi.focus.26024111}
}
EUVIMED